Complement-mediated inflammation exacerbates the tissue injury of ischaemic necrosis in heart attacks and strokes, the most common causes of death in developed countries. Large infarct size increases immediate morbidity and mortality and, in survivors of the acute event, larger non-functional scars adversely affect long-term prognosis. There is thus an important unmet medical need for new cardioprotective and neuroprotective treatments. We have previously shown that human C-reactive protein (CRP), the classical acute-phase protein that binds to ligands exposed in damaged tissue and then activates complement 1 , increases myocardial and cerebral infarct size in rats subjected to coronary or cerebral artery ligation, respectively 2,3 . Rat CRP does not activate rat complement, whereas human CRP activates both rat and human complement 4 . Administration of human CRP to rats is thus an excellent model for the actions of endogenous human CRP 2,3 . Here we report the design, synthesis and efficacy of 1,6-bis(phosphocholine)-hexane as a specific small-molecule inhibitor of CRP. Five molecules of this palindromic compound are bound by two pentameric CRP molecules, crosslinking and occluding the ligand-binding B-face of CRP and blocking its functions. Administration of 1,6-bis(phosphocholine)-hexane to rats undergoing acute myocardial infarction abrogated the increase in infarct size and cardiac dysfunction produced by injection of human CRP. Therapeutic inhibition of CRP is thus a promising new approach to cardioprotection in acute myocardial infarction, and may also provide neuroprotection in stroke. Potential wider applications include other inflammatory, infective and tissue-damaging conditions characterized by increased CRP production, in which binding of CRP to exposed ligands in damaged cells may lead to complement-mediated exacerbation of tissue injury.
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No inhibitors of calcium-dependent binding of human CRP to phosphocholine, the natural ligand for which it has highest affinity, were detected in a screen of the comprehensive 500,000 smallmolecule library of a pharmaceutical company. We therefore rationally designed novel ligands for CRP based on the crystal structure of the CRP-phosphocholine complex 5 and the structure of a potent drug we have developed that targets the homologous protein, serum amyloid P component (SAP) 6 . The SAP inhibitor consists of two D-proline residues linked by a hexanoyl chain, and the SAP-drug complex contains two SAP molecules crosslinked by five drug molecules, with each D-proline located in the calcium-dependent ligand-binding pocket of an SAP protomer 6 . In the CRP-phosphocholine complex, one phosphocholine molecule is positioned parallel to the pentamer surface on each of the five CRP subunits, and is oriented with the choline moieties, pinned between Glu 81 and Phe 66, towards the fivefold axis 5 . Two oxygen atoms of the phosphocholine phosphate group directly coordinate the two bound calcium ions of CRP, but the third is oriented away from the protein surface 5 , providing a suitable exit point to direct a crosslinking chain towards a putative twofold-axis-related subunit of an adjacent CRP pentamer. We selected a six-carbon linker to 50 for inhibition by bis(PC)-H of CRP binding to immobilized pneumococcal C-polysaccharide was ,2 mM, compared to ,20 mM for free phosphocholine. Bis(PC)-H also blocked complement activation by human CRP and C-polysaccharide in human serum. In mixtures of drug and CRP at molar ratios between 1:1 and 1:1,000 with respect to CRP protomers, all CRP molecules became associated in pairs, as shown by size-exclusion chromatography, electron microscopy and mass spectrometry (Fig. 2) . Addition of bis(PC)-H to isolated CRP, or to CRP in whole serum, resulted in disappearance of CRP immunoreactivity using a monoclonal antibody assay (Roche) specific for a calcium-dependent epitope on the binding (B) face of the CRP molecule 7 , suggesting that this epitope was occluded in the CRP-drug complex. The IC 50 was at the ratio of three bis(PC)-H per two pentameric CRP molecules. Covalent crosslinking of CRP molecules in the CRP-drug complex, followed by fragmentation and mass spectrometric analysis (data not shown), confirmed the B face-B face association.
The X-ray crystal structure of the CRP-bis(PC)-H complex revealed two pentameric CRP molecules lying face-to-face with a common fivefold symmetry axis, crosslinked via their phosphocholine-binding sites by five drug molecules ( . However, a considerably worse fit (r.m.s. all Ca ¼ 0.8 Å ) was observed upon overlaying complete pentamers. This was due to a systematic movement of b-strands by ,1 Å towards the fivefold axis, resulting in a contraction of ,2 Å in the pore diameter at the centre of the pentamer in the CRP-bis(PC)-H complex. There are ,25% more inter-atomic contacts of less than 3.5 Å per CRP subunit than in the complex with phosphocholine. Identical cryopreservation methods were used during data collection, indicating that this effect is a specific consequence of bis(PC)-H binding by CRP. There are also two additional calcium ions bound per subunit: one by the side chain of Asp 60 and the carbonyl of Asn 59, close to the ligand-binding double calcium site, and the other by the main-chain carbonyl of Glu 70 and the side-chain carboxylate of the same residue from the twofold-symmetry-related subunit of the adjacent pentamer, providing decamer stabilization. The ligand fields of these calcium ions are limited, and they are likely to be occupied only by virtue of the high calcium ion concentration (50 mM) in the crystallization cocktail. Further decamer stability is provided by ten inter-pentamer ion pairs between Lys 69 N1 and Glu 85'Od. All of these interactions between pentamers are orthogonal to the observed direction of contraction, and are unlikely to be its cause.
The electron density for the phosphocholine component of bis(PC)-H and the first carbon of the crosslinker is very good but, not unexpectedly for such a flexible linker, the density for the central four carbon atoms is weaker (Fig. 3c) . In order to fit these atoms within the space available and to achieve the required approach path to the phosphate groups, there is an unfavourable eclipsed rotamer about the C3-C4 bond of the linker. However, 1,5-bis(phosphocholine)-pentane, with a shorter linker, was bound with substantially lower affinity (K d ,3.7 mM), and there was no binding at all to the more rigid bis(phosphocholine)-dimethylcyclohexane ( Fig. 1 and Supplementary Information). In contrast 1,7-bis(phosphocholine)-heptane ( Fig. 1 ; K d ,300 nM) evidently had sufficient linker length and flexibility to permit this mechanism of drug-protein interaction.
Bolus intravenous or intraperitoneal injections in mice and rats of up to 1 mmol kg 21 bis(PC)-H in physiological saline solution, or continuous infusion at 1 mmol kg 21 per day for seven days via subcutaneous osmotic pump, were tolerated without noticeable adverse effects, and inhibited binding of injected human CRP to other ligands and its reactivity using the Roche assay 7 . The plasma half-life of bis(PC)-H in mice was ,90 min. Continuous infusion of 1 mmol bis(PC)-H per kg per day in rats completely blocked the effects of daily subcutaneous injections of 40 mg kg 21 human CRP (,1.74 mmol CRP protomer), despite the presence of rat CRP, which binds the drug with K d ,150 nM, circulates at 300-500 mg l 21 , and is produced at the rate of ,10 mmol protomer per kg per day.
Clinical treatment with a CRP inhibitor could be started immediately upon admission to hospital following acute myocardial infarction-this would precede the acute phase CRP response, which starts about 6 h after onset of pain and peaks at about 50 h (refs 8, 9). We therefore initiated infusion of bis(PC)-H before coronary artery ligation in rats, and gave the first of five daily subcutaneous injections of human CRP immediately after recovery from surgery, closely replicating the initial dynamics of the endogenous human CRP response. Administration of human CRP was associated with increased mortality compared to vehicle-only controls, as we have previously reported 2 . In contrast, there were no deaths among the rats receiving bis(PC)-H in addition to CRP (Table 1 ) (Fisher's exact test for comparison of mortality in all groups, P ¼ 0.08). Infarct size on day 5 was substantially larger in the rats treated with CRP (unpaired t-test, P ¼ 0.0001 compared to vehicle-treated rats), but in rats receiving bis(PC)-H as well as CRP, infarct size was the same as in vehicle-only controls (Table 1) . Electro-and echocardiographic indices of cardiac function on day 5 were consistent with the larger infarcts in CRP-treated rats and with a protective effect of bis(PC)-H (Table 1) .
At bleed-out on day 5, 24 h after the last dose of human CRP, the mean (^s.d.) concentration of human CRP in the serum of CRP-treated rats was 16.7^10.6 mg l 21 , but human CRP was detectable by standard immunoassay in only 4 of the 11 CRP-treated rats receiving bis(PC)-H (mean 3.3^1.5 mg 2l ), and was not detected at all by the Roche assay, demonstrating complex formation between bis(PC)-H and CRP. Continuous infusion of bis(PC)-H thus resulted in accelerated clearance of human CRP and blocked its function.
In a separate experiment, administration of the same dose of bis(PC)-H to rats (n ¼ 11) that underwent coronary artery ligation but did not receive human CRP had no effect on infarct size at day 5, compared to coronary artery ligation controls receiving vehicle alone (n ¼ 6). The mean infarct size (^s.d.) as a percentage of the left ventricle was 19.0^1.9% for the bis(PC)-H group and 20.0^2.0% for the vehicle group. There was also no difference in haemodynamic measures, indicating that bis(PC)-H had no significant cardiovascular effect in the absence of human CRP.
The physiological role of human CRP is unknown because no deficiency or structural polymorphism in human CRP, or experimental CRP knockout, has yet been reported. Experimental animal studies suggest that CRP may contribute to innate immunity, can be anti-inflammatory, and may protect against autoimmunity, and we have shown that the administration of human CRP exacerbates pre-existing tissue damage in a complement-dependent fashion 2, 3 . Previously reported pro-inflammatory effects of human CRP preparations on cells in vitro were due to bacterial endotoxin and other contaminants rather than CRP itself [10] [11] [12] , and pure human CRP is not pro-inflammatory when injected into healthy animals 12, 13 . Furthermore, transgenic human CRP is not pro-atherogenic or pro-thrombotic in apolipoprotein-E-knockout mice 14 . However, the evolutionary conservation of CRP does not exclude potentially harmful effects-although CRP may have evolved to promote beneficial functions, it might also enhance lesion severity, especially in post-reproductive-age diseases such as atherothrombosis, autoimmune and other chronic inflammatory conditions, which are not subject to evolutionary pressure. Our rationally designed CRPtargeting drug demonstrates that CRP inhibition is a valid therapeutic strategy that is unlikely to have adverse effects, and that may prove informative about the physiological and pathological roles of human CRP.
METHODS
Reagents and assays. Human CRP was isolated from malignant ascites fluid as reported 3, 13 . Human CRP was assayed by the Roche 7 and Dade-Behring methods 15 and by electroimmunoassay 16 . Rat CRP and complement C3 were measured by electroimmunoassay 4 . Calcium-dependent binding of 125 I-labelled CRP to pneumococcal C-polysaccharide (Statens Serum Institut) and modified human low-density lipoprotein 17 , which were covalently immobilized on Corning Costar N-hydroxysuccinimide microtitre plates, was compared in the presence and absence of inhibitor compounds. Binding of CRP to phosphoethanolamine-Sepharose was determined as reported previously for SAP 18 . Activation of complement in whole human serum by CRP and C-polysaccharide in the presence and absence of bis(PC)-H was monitored by two-dimensional immunolectrophoresis 4 with monospecific antiserum against human C3.
Binding affinity of CRP for ligands in solution in 0.01 M Tris, 0.14 M NaCl, 0.002 M CaCl 2 , 0.1% NaN 3 pH 8.0 (TC buffer plus azide) was measured at 37 8C by isothermal titration calorimetry 6 . The effects of bis(PC)-H on CRP molecules were monitored by chromatography on a Superdex 200 HR10/30 column in the Å KTA Explorer 100 HPLC system (Amersham Biosciences) eluted with TC buffer, by uranyl acetate negative-staining electron microscopy on carbon grids, and by electrospray mass spectrometry (Supplementary Information). Myocardial infarction. ALZET osmotic mini-pumps, delivering 10 ml h 21 for seven days, were implanted subcutaneously in male Wistar rats (200-220 g) two days before coronary artery ligation. Groups A and B received TC buffer; and group C received 1.0 M bis(PC)-H in TC buffer, providing 1 mmol kg 21 per day. Coronary artery ligation or sham operations were performed under intraperitoneal anaesthesia with 75 mg kg 21 ketamine, 0.6 mg kg 21 xylazine and 0.2 mg kg 21 atropine 19, 20 , and post-operative atipamezole 0.5 mg kg 21 two days after pump implantation. Five daily subcutaneous injections of either TC buffer alone (group A) or human CRP at 40 mg kg 21 per day in TC buffer (groups B and C) were given, starting immediately after recovery from coronary surgery. Echocardiography (10-22 MHz probe, Dynamic Imaging) 21, 22 , right carotid artery cannulation (using a pressure-transducer tipped catheter 1.4 F, Millar Instrument Inc.) and cardiac catheterization were performed on day 5, with the rats under isofluorane anaesthesia. The rats were then bled, and their hearts excised, cleaned, weighed and frozen. Frozen hearts were then cut transversely into 2.5-mm slices and stained with 1% (w/v) 2,3,5-triphenyl tetrazolium chloride in phosphate buffer. Infarct size was measured by planimetry (using an MCID image analysis system, Imaging Research Inc.) on formalin-fixed, glassmounted sections, and confirmed by dissection and weighing. All treatments and measurements were performed by an experimenter blind to the treatment group. 
